BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cianci R, Franza L, Schinzari G, Rossi E, Ianiro G, Tortora G, Gasbarrini A, Gambassi G, Cammarota G. The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. Int J Mol Sci 2019;20:E501. [PMID: 30682772 DOI: 10.3390/ijms20030501] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Franza L, Costantini B, Corrado G, Spanu T, Covino M, Ojetti V, Quagliozzi L, Biscione A, Taccari F, Fagotti A, Scambia G, Tamburrini E. Risk factors for bloodstream infections in gynecological cancer. Int J Gynecol Cancer 2020;30:245-51. [PMID: 31915135 DOI: 10.1136/ijgc-2019-000861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Naqash AR, Kihn-Alarcón AJ, Stavraka C, Kerrigan K, Maleki Vareki S, Pinato DJ, Puri S. The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. Ann Transl Med 2021;9:1034. [PMID: 34277834 DOI: 10.21037/atm-20-6427] [Reference Citation Analysis]
3 Cianci R, Franza L, Massaro MG, Borriello R, De Vito F, Gambassi G. The Interplay between Immunosenescence and Microbiota in the Efficacy of Vaccines. Vaccines (Basel) 2020;8:E636. [PMID: 33147686 DOI: 10.3390/vaccines8040636] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
4 Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, Maruzzo M, Mosca A, Pisano C, Verzoni E, Zucali PA. Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient? Curr Oncol Rep 2021;23:147. [PMID: 34748099 DOI: 10.1007/s11912-021-01140-9] [Reference Citation Analysis]
5 Amedei A, Barceló-Coblijn G. Editorial of Special Issue "The Interplay of Microbiome and Immune Response in Health and Diseases". Int J Mol Sci 2019;20:E3708. [PMID: 31362374 DOI: 10.3390/ijms20153708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Baritaki S, de Bree E, Chatzaki E, Pothoulakis C. Chronic Stress, Inflammation, and Colon Cancer: A CRH System-Driven Molecular Crosstalk. J Clin Med 2019;8:E1669. [PMID: 31614860 DOI: 10.3390/jcm8101669] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
7 Vivarelli S, Falzone L, Leonardi GC, Salmeri M, Libra M. Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). Int J Oncol 2021;59:75. [PMID: 34396439 DOI: 10.3892/ijo.2021.5255] [Reference Citation Analysis]
8 Pinato DJ, Gramenitskaya D, Altmann DM, Boyton RJ, Mullish BH, Marchesi JR, Bower M. Antibiotic therapy and outcome from immune-checkpoint inhibitors. J Immunother Cancer 2019;7:287. [PMID: 31694714 DOI: 10.1186/s40425-019-0775-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 12.0] [Reference Citation Analysis]
9 Prasetya RA, Metselaar-Albers M, Engels F. Concomitant use of analgesics and immune checkpoint inhibitors in non-small cell lung cancer: A pharmacodynamics perspective. Eur J Pharmacol 2021;906:174284. [PMID: 34174268 DOI: 10.1016/j.ejphar.2021.174284] [Reference Citation Analysis]
10 Zadka Ł, Chrabaszcz K, Buzalewicz I, Wiercigroch E, Glatzel-Plucińska N, Szleszkowski Ł, Gomułkiewicz A, Piotrowska A, Kurnol K, Dzięgiel P, Jurek T, Malek K. Molecular profiling of the intestinal mucosa and immune cells of the colon by multi-parametric histological techniques. Sci Rep 2021;11:11309. [PMID: 34050214 DOI: 10.1038/s41598-021-90761-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Franza L, Carusi V, Nucera E, Pandolfi F. Luteolin, inflammation and cancer: Special emphasis on gut microbiota. Biofactors 2021;47:181-9. [PMID: 33507594 DOI: 10.1002/biof.1710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Gianfredi V, Nucci D, Salvatori T, Dallagiacoma G, Fatigoni C, Moretti M, Realdon S. Rectal Cancer: 20% Risk Reduction Thanks to Dietary Fibre Intake. Systematic Review and Meta-Analysis. Nutrients 2019;11:E1579. [PMID: 31336939 DOI: 10.3390/nu11071579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
13 Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. Integr Cancer Ther 2019;18:1534735419876351. [PMID: 31517538 DOI: 10.1177/1534735419876351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
14 Piccioni A, Franza L, Brigida M, Zanza C, Torelli E, Petrucci M, Nicolò R, Covino M, Candelli M, Saviano A, Ojetti V, Franceschi F. Gut Microbiota and Acute Diverticulitis: Role of Probiotics in Management of This Delicate Pathophysiological Balance. J Pers Med 2021;11:298. [PMID: 33919818 DOI: 10.3390/jpm11040298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Martins Lopes MS, Machado LM, Ismael Amaral Silva PA, Tome Uchiyama AA, Yen CT, Ricardo ED, Mutao TS, Pimenta JR, Shimba DS, Hanriot RM, Peixoto RD. Antibiotics, cancer risk and oncologic treatment efficacy: a practical review of the literature. Ecancermedicalscience 2020;14:1106. [PMID: 33144874 DOI: 10.3332/ecancer.2020.1106] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Carbone C, Piro G, Di Noia V, D'Argento E, Vita E, Ferrara MG, Pilotto S, Milella M, Cammarota G, Gasbarrini A, Tortora G, Bria E. Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Mediators Inflamm 2019;2019:7652014. [PMID: 31827379 DOI: 10.1155/2019/7652014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
17 Zhang X, Pan Z. Influence of microbiota on immunity and immunotherapy for gastric and esophageal cancers. Gastroenterol Rep (Oxf) 2020;8:206-14. [PMID: 32665852 DOI: 10.1093/gastro/goaa014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]